After a surprise failure in advanced liver cancer, Merck & Co. and Eisai are hoping new data can make their Keytruda-Lenvima combination a standard of care in intermediate-stage disease. | After a ...

The global Animal Antibacterial and Antibiotics Market is projected to grow from approximately USD 4.9 billion in 2024 to ...

Investigators compared outcomes between patients with stage II/III colon cancer given adjuvant aspirin and those given ...

The efficacy of rucaparib plus nivolumab was compared with rucaparib monotherapy as maintenance treatment for ovarian cancer.

Bayer is thought to be closest behind Merck with eliapixant, reporting encouraging results in the phase 2b PAGANINI trial last September, which used the same efficacy endpoint as Merck's studies.

What's the BIOSECURE Act? Why is Merck nonchalant about Summit's Keytruda rival? What did Roivant buy from Bayer? We answer ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

The decision comes just a few months after Bayer reported encouraging results for eliapixant in chronic cough – the same indication sought by Merck for gefapixant – saying it hit its objective ...

Getting more effective drugs for patients in need as quickly as possible should be the ultimate reward and objective.

With a market capitalization of just $1.9 billion, Recursion still provides a potentially good entry point for investors, but ...

Arcus Biosciences develops late-stage immunotherapies, with Domvanalimab and Casdatifan leading the way. See why I rate RCUS ...